Therefore, a combination of [18F]FDG and PSMA-targeted PET/CT may be able to detect clinically relevant glucose metabolic viable tumor lesions with low or no PSMA expression (mismatch lesions) in the advanced mCRPC setting. Here, FOLH1 is linked to neoplasm.